In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Does Roche Have It Right?

Executive Summary

Roche's hostile tender offer for Ventana Medical Systems, and to a lesser extent its recent acquisitions of life science tools companies this year, highlight the firm's belief in diagnostics and its bet that personalized medicine--an area where innovative platforms and molecular test content will play significant if separate roles--will be key to its long-term growth. It could be an expensive and risky strategy that will take years to come to fruition.
Advertisement

Related Content

With Genoptix, Novartis Continues Its Diagnostics Build-up
With DxS, Qiagen Moves into Personalized Medicine
Tethys BioScience Inc.
In Vitro Diagnostics: Innovation and Integration
Business & Technology Briefs (08/2007)
Wake-up Calls in IVD
GE Grabs the Spotlight in IVD
Siemens acquires Bayer Diagnostics, Creates Integrated Diagnostics Powerhouse
Drug/Diagnostic Co-Development: When to Begin the Tandem Ride
GE's Personalized Play for Amersham

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV002973

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel